cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc21phz7
title: CCDC 1897509: Experimental Crystal Structure Determination

description: Related Article: Dmitry A. Vasilenko, Victor B. Rybakov, Elena  B. Averina|2019|CSD Communication|||
description: Related Article: Dmitry A. Vasilenko, Sevastian E. Dronov, Dzianis U. Parfiryeu, Kirill S. Sadovnikov, Kseniya N. Sedenkova, Yuri K. Grishin, Victor B. Rybakov, Tamara S. Kuznetsova, Elena B. Averina|2021|Org.Biomol.Chem.|19|6447|doi:10.1039/D1OB00816A
DOI: 10.5517/ccdc.csd.cc24m824
title: CCDC 1984715: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m835
title: CCDC 1984716: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m846
title: CCDC 1984717: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m857
title: CCDC 1984718: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m879
title: CCDC 1984720: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m88b
title: CCDC 1984721: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5517/ccdc.csd.cc24m89c
title: CCDC 1984722: Experimental Crystal Structure Determination

description: Related Article: Alexander V. Artem'ev, Maria P. Davydova, Mariana I. Rakhmanova, Irina Yu. Bagryanskaya, Denis P. Pishchur|2021|Inorg.Chem.Front.|8|3767|doi:10.1039/D1QI00556A
DOI: 10.5281/zenodo.4605619
title: Fall events and daily activities from a sensorized smart floor

description: Data about fall events and daily activities from a smart floor wired with a matrix of sixteen pressure sensors. The dataset includes: sensor data gathered on a session simulating falls. The data was gathered from a proprietary setting of an array of pressure sensors mounted on a 1.2m x 1.2m floor setting with 16 sensors. The dataset also includes the questionary that each participant filled and source code for a program that collects the data from sensors and manages the data gathering process. Proprietary program that gatheres data from sensors and also manages the fall event testing. The program also includes a simple graphical representation showing current sensor activity.
DOI: 10.5281/zenodo.3991750
title: Fall events and daily activities from a sensorized smart floor

description: Data about fall events and daily activities from a smart floor wired with a matrix of sixteen pressure sensors. The dataset includes: sensor data gathered on a session simulating falls. The data was gathered from a proprietary setting of an array of pressure sensors mounted on a 1.2m x 1.2m floor setting with 16 sensors. The dataset also includes the questionary that each participant filled and source code for a program that collects the data from sensors and manages the data gathering process. Proprietary program that gatheres data from sensors and also manages the fall event testing. The program also includes a simple graphical representation showing current sensor activity.
DOI: 10.5517/ccdc.csd.cc26n7hm
title: CCDC 2045240: Experimental Crystal Structure Determination

description: Related Article: Ahmad Hobballah, Federica Arrigoni, Catherine Elleouet, Claudio Greco, Maxime Laurans, François Y. Pétillon, Philippe Schollhammer|2021|Inorg.Chem.Front.|8|3659|doi:10.1039/D1QI00006C
DOI: 10.5517/ccdc.csd.cc26n7jn
title: CCDC 2045241: Experimental Crystal Structure Determination

description: Related Article: Ahmad Hobballah, Federica Arrigoni, Catherine Elleouet, Claudio Greco, Maxime Laurans, François Y. Pétillon, Philippe Schollhammer|2021|Inorg.Chem.Front.|8|3659|doi:10.1039/D1QI00006C
DOI: 10.5517/ccdc.csd.cc26n7kp
title: CCDC 2045242: Experimental Crystal Structure Determination

description: Related Article: Ahmad Hobballah, Federica Arrigoni, Catherine Elleouet, Claudio Greco, Maxime Laurans, François Y. Pétillon, Philippe Schollhammer|2021|Inorg.Chem.Front.|8|3659|doi:10.1039/D1QI00006C
DOI: 10.5517/ccdc.csd.cc26n7lq
title: CCDC 2045243: Experimental Crystal Structure Determination

description: Related Article: Ahmad Hobballah, Federica Arrigoni, Catherine Elleouet, Claudio Greco, Maxime Laurans, François Y. Pétillon, Philippe Schollhammer|2021|Inorg.Chem.Front.|8|3659|doi:10.1039/D1QI00006C
DOI: 10.5517/ccdc.csd.cc26yz9g
title: CCDC 2054596: Experimental Crystal Structure Determination

description: Related Article: Pradnya Kulkarni, Dhrubajyoti Datta, Raghunath O. Ramabhadran, Krishna Ganesh|2021|Org.Biomol.Chem.|19|6534|doi:10.1039/D1OB01097B
DOI: 10.5517/ccdc.csd.cc2788qj
title: CCDC 2063537: Experimental Crystal Structure Determination

description: Related Article: Dmitry A. Vasilenko, Sevastian E. Dronov, Dzianis U. Parfiryeu, Kirill S. Sadovnikov, Kseniya N. Sedenkova, Yuri K. Grishin, Victor B. Rybakov, Tamara S. Kuznetsova, Elena B. Averina|2021|Org.Biomol.Chem.|19|6447|doi:10.1039/D1OB00816A
description: Related Article: V. B. Rybakov, D. A. Vasilenko, K. S. Sadovnikov, S. E. Dronov, E. B. Averina|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc27pm8v
title: CCDC 2076357: Experimental Crystal Structure Determination

description: Related Article: Robby Vroemans, Sergio R. Ribone, Joice Thomas, Luc Van Meervelt, Thierry Ollevier, Wim Dehaen|2021|Org.Biomol.Chem.|19|6521|doi:10.1039/D1OB00784J
DOI: 10.5517/ccdc.csd.cc27pm9w
title: CCDC 2076358: Experimental Crystal Structure Determination

description: Related Article: Robby Vroemans, Sergio R. Ribone, Joice Thomas, Luc Van Meervelt, Thierry Ollevier, Wim Dehaen|2021|Org.Biomol.Chem.|19|6521|doi:10.1039/D1OB00784J
DOI: 10.5517/ccdc.csd.cc27pmbx
title: CCDC 2076359: Experimental Crystal Structure Determination

description: Related Article: Robby Vroemans, Sergio R. Ribone, Joice Thomas, Luc Van Meervelt, Thierry Ollevier, Wim Dehaen|2021|Org.Biomol.Chem.|19|6521|doi:10.1039/D1OB00784J
DOI: 10.5517/ccdc.csd.cc27pmcy
title: CCDC 2076360: Experimental Crystal Structure Determination

description: Related Article: Robby Vroemans, Sergio R. Ribone, Joice Thomas, Luc Van Meervelt, Thierry Ollevier, Wim Dehaen|2021|Org.Biomol.Chem.|19|6521|doi:10.1039/D1OB00784J
DOI: 10.5517/ccdc.csd.cc27q6sz
title: CCDC 2076931: Experimental Crystal Structure Determination

description: Related Article: Marlène Palluel, Liza El Khoury, Nathalie Daro, Sonia Buffière, Michael Josse, Mathieu Marchivie, Guillaume Chastanet|2021|Inorg.Chem.Front.|8|3697|doi:10.1039/D1QI00482D
DOI: 10.6084/m9.figshare.15066624
title: RNA Seq

description: <b>Differential gene expression in mesenteric arteries and perivascular adipose tissue from young and old mice. </b>
DOI: 10.6084/m9.figshare.15066624.v1
title: RNA Seq

description: <b>Differential gene expression in mesenteric arteries and perivascular adipose tissue from young and old mice. </b>
DOI: 10.5281/zenodo.5140504
title: dual scRNA-seq analysis of P. vivax infected hepatocytes

description: Malaria-causing P. vivax parasites can linger in the human liver for weeks to months and then reactivate to cause recurrent blood-stage infection. While recognized as an important point of intervention for malaria eradication, very little is known about the molecular composition of the actively-replicating and quiescent intracellular P. vivax parasite populations, nor the molecular features and dynamics that underlie host cell responses to infection in humans. Here, we leverage a bioengineered human microliver platform to culture Thai clinical isolates of P. vivax in primary human hepatocytes and to conduct transcriptional profiling of infected cultures. By coupling targeted enrichment strategies with bulk and single-cell analyses, we capture both parasite and host transcripts in individual infected hepatocytes throughout the course of infection. We define stage-specific transcriptional signatures and identify a novel population of actively replicating parasites, sharing features with sexual blood-stages. Within infected liver cells, we find that infection suppresses transcription of key hepatocyte function genes, and that P. vivax elicits an innate immune response that can be manipulated to control infection in curative therapy mode. Our work provides an extendible framework and a valuable resource for understanding host-parasite interactions and reveals new insights into the biology of relapsing human malaria.
description: Sample / time-points naming scheme: day of the sampling, replicate, type of libraries. "Seq" means direct sequencing of the corresponding SeqWell library, "Cap" means post-SeqWell library construction P. vivax hybrid capture.
DOI: 10.5281/zenodo.5141743
title: First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement

description: Dataset from the article Latib A, Mangieri A, Vezzulli P, Spagnolo P, Sardanelli F, Fellegara G, Pagnesi M, Giannini F, Falini A, Gorla R, Montorfano M, Bedogni F, Colombo A, Popma J, Merhi WM, De Marco F. First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Apr 13;13(7):860-868. doi: 10.1016/j.jcin.2019.11.017. PMID: 32273098. <strong>Abstract</strong> <strong>Objectives: </strong>This study sought to evaluate the feasibility of complete cerebral protection during transcatheter aortic valve replacement (TAVR) with a novel embolic protection device. <strong>Background: </strong>Evidences and data about new cerebral embolic protection devices are lacking and scarce. <strong>Methods: </strong>A prospective, nonrandomized, multicenter, first-in-man pilot study designed to evaluate the efficacy and safety of cerebral embolic protection utilizing the Emblok embolic protection system (Innovative Cardiovascular Solutions, Grand Rapids, Michigan) during TAVR. The Emblok is a transfemoral aortic filter that provide full coverage of the epiaortic vessels. Brain diffusion-weighted magnetic resonance imaging (DW-MRI) was performed at baseline and 2 to 5 days after TAVR. Primary endpoints were technical success and immediate cerebral embolic burden after TAVR, defined as number and volume of new brain lesions detected with DW-MRI at days 2 to 5 post-TAVR compared with baseline. <strong>Results: </strong>A total of 20 subjects were enrolled. The Emblok system was successfully positioned in all the cases. At 30-day follow-up, no major adverse cardiovascular and cerebrovascular events occurred. Nineteen (95%) patients had new ischemic defects at post-procedural DW-MRI. The median number of new lesions per patient was 10.00 (interquartile range [IQR]: 4.75 to 15.25). The total new lesion volume was 199.9 mm<sup>3</sup> (IQR: 83.9 to 447.5 mm<sup>3</sup>) and the mean lesion volume per lesion was 42.5 mm<sup>3</sup> (IQR: 21.5 to 75.6 mm<sup>3</sup>). Histopathologic analysis showed evidence of significant debris in 18 (90%) filters. <strong>Conclusions: </strong>The Emblok embolic protection system appears to be feasible and safe during TAVR. The device was successfully placed and retrieved in all cases and no neurological events were observed. Cerebral total new lesion volume was similar to other trials on cerebral protection during TAVR, thus warranting a larger study. (European Study Evaluating the Emblok Embolic Protection System During TAVR.
DOI: 10.5281/zenodo.5141742
title: First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement

description: Dataset from the article Latib A, Mangieri A, Vezzulli P, Spagnolo P, Sardanelli F, Fellegara G, Pagnesi M, Giannini F, Falini A, Gorla R, Montorfano M, Bedogni F, Colombo A, Popma J, Merhi WM, De Marco F. First-in-Man Study Evaluating the Emblok Embolic Protection System During Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 Apr 13;13(7):860-868. doi: 10.1016/j.jcin.2019.11.017. PMID: 32273098. <strong>Abstract</strong> <strong>Objectives: </strong>This study sought to evaluate the feasibility of complete cerebral protection during transcatheter aortic valve replacement (TAVR) with a novel embolic protection device. <strong>Background: </strong>Evidences and data about new cerebral embolic protection devices are lacking and scarce. <strong>Methods: </strong>A prospective, nonrandomized, multicenter, first-in-man pilot study designed to evaluate the efficacy and safety of cerebral embolic protection utilizing the Emblok embolic protection system (Innovative Cardiovascular Solutions, Grand Rapids, Michigan) during TAVR. The Emblok is a transfemoral aortic filter that provide full coverage of the epiaortic vessels. Brain diffusion-weighted magnetic resonance imaging (DW-MRI) was performed at baseline and 2 to 5 days after TAVR. Primary endpoints were technical success and immediate cerebral embolic burden after TAVR, defined as number and volume of new brain lesions detected with DW-MRI at days 2 to 5 post-TAVR compared with baseline. <strong>Results: </strong>A total of 20 subjects were enrolled. The Emblok system was successfully positioned in all the cases. At 30-day follow-up, no major adverse cardiovascular and cerebrovascular events occurred. Nineteen (95%) patients had new ischemic defects at post-procedural DW-MRI. The median number of new lesions per patient was 10.00 (interquartile range [IQR]: 4.75 to 15.25). The total new lesion volume was 199.9 mm<sup>3</sup> (IQR: 83.9 to 447.5 mm<sup>3</sup>) and the mean lesion volume per lesion was 42.5 mm<sup>3</sup> (IQR: 21.5 to 75.6 mm<sup>3</sup>). Histopathologic analysis showed evidence of significant debris in 18 (90%) filters. <strong>Conclusions: </strong>The Emblok embolic protection system appears to be feasible and safe during TAVR. The device was successfully placed and retrieved in all cases and no neurological events were observed. Cerebral total new lesion volume was similar to other trials on cerebral protection during TAVR, thus warranting a larger study. (European Study Evaluating the Emblok Embolic Protection System During TAVR.
DOI: 10.5283/epub.46411
title: Data Archive of "Spin-Orbit Coupling in Functionalized Graphene"
DOI: 10.5525/gla.researchdata.1170
title: Summary statistics from a genome-wide association study of carotid intima-media thickness in UK Biobank.
DOI: 10.6084/m9.figshare.15066660
title: Supplementary Material for: Short-Term Effects of Dexamethasone versus Betamethasone on Ultrasonic Measures of Fetal Well-Being: Cohort from a Blinded, Randomized Trial

description: <b><i>Introduction:</i></b> Maternal corticosteroid administration for anticipated preterm birth is common; however, the corticosteroid effect on fetal ultrasound and cardiotocograph (CTG) remains contested. This study aimed to evaluate short-term ultrasound and CTG impact of (a) dexamethasone versus betamethasone (b) pooled corticosteroid effect. <b><i>Methods:</i></b> Substudy of blinded randomized trial of dexamethasone versus betamethasone (given &lt;34 weeks). Umbilical artery (UA), middle cerebral artery (MCA), ductus venosus (DV), and uterine artery Doppler, myocardial performance index (MPI), biophysical profile (BPP), and CTG measured pre-corticosteroid then 1, 2, 4, and 7 days post-corticosteroid. <b><i>Results:</i></b> Of 47 fetuses (39 singleton; 4 dichorionic, diamniotic twins; and 4 monochorionic, diamniotic twins) in the February 2012–2013 period, 24 received dexamethasone and 23 betamethasone at average gestation 29.8 ± 2.9 weeks. Thirteen pregnancies (30%) had pre-corticosteroid fetal concerns (estimated weight &lt;10th centile and/or abnormal UA/MCA Doppler). Few significant differences were seen post-corticosteroid: DV pulsatility index and right MPI initially decreased 15–20%, and average BPP decreased slightly on days 1–2. There were no major differential effects of dexamethasone versus betamethasone. <b><i>Discussion/Conclusion:</i></b> No substantive post-corticosteroid effects were seen for most ultrasound/CTG measures in fetuses with heightened preterm birth risk but predominantly normal pre-corticosteroid measures. Clinically, this suggests avoiding overreliance on individual measures for delivery decisions post-corticosteroid; equally, multiple/marked ultrasound changes suggest true pathology and not corticosteroid effect.
DOI: 10.5281/zenodo.5141789
title: GWB_data

description: This data was used in the creation of figures for:<br> Clarifying transfer function approximations for the large-scale gravitational wave background inΛCDM
DOI: 10.5281/zenodo.5141788
title: GWB_data

description: This data was used in the creation of figures for:<br> Clarifying transfer function approximations for the large-scale gravitational wave background inΛCDM
DOI: 10.5281/zenodo.5141786
title: Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System

description: Dataset from Fontana GP, Bedogni F, Groh M, Smith D, Chehab BM, Garrett HE Jr, Yong G, Worthley S, Manoharan G, Walton A, Hermiller J, Dhar G, Waksman R, Ramana RK, Mahoney P, Asch FM, Chakravarty T, Jilaihawi H, Makkar RR. Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System. JACC Cardiovasc Interv. 2020 Nov 9;13(21):2467-2478. doi: 10.1016/j.jcin.2020.06.041. Epub 2020 Jul 20. PMID: 33153563. <strong>Abstract</strong> <strong>Objectives: </strong>The aim of this study was to characterize the safety profile of an intra-annular self-expanding valve with a next-generation low-profile delivery system (DS). <strong>Background: </strong>Key design modifications to the FlexNav DS include the addition of a hydrophilic-coated, integrated sheath and stability layer to facilitate gradual, controlled deployment in vessels with diameter ≥5 mm. <strong>Methods: </strong>Patients were pooled from 2 concurrent prospective, multicenter, single-arm studies (FlexNav DS arm of PORTICO IDE [Portico Re-Sheathable Transcatheter Aortic Valve System U.S. IDE Trial] [n = 134] and the FlexNav EU CE Mark Study [n = 46]) for the analysis. The primary endpoint was Valve Academic Research Consortium-2-defined major vascular complications at 30 days. Clinical outcomes and valve performance were assessed through 30 days by an independent clinical events committee and an echocardiography core laboratory, respectively. <strong>Results: </strong>One hundred forty high-risk and 40 extreme-risk subjects enrolled between October 15, 2018, and December 10, 2019, from 28 sites in the United States, Australia, and Europe who underwent attempted transfemoral Portico valve implantation were included. The mean age was 85.1 ± 5.6 years, 60% were women, the mean Society of Thoracic Surgeons score was 5.3%, and 96.1% presented with ≥1 frailty factor. Technical device success was 96.7%. At 30 days, the rate of major vascular complications was 5.0%, with 4.4% of complications adjudicated as access site-related (3.3% transcatheter aortic valve replacement DS access site-related). Death (0.6%) and disabling stroke (1.1%) were rare. The rate of new permanent pacemaker implantation was 15.4%. Echocardiography revealed a mean gradient of 7.1 ± 3.2 mm Hg, mean valve area of 1.77 ± 0.41 cm<sup>2</sup>, and a 4.1% rate of moderate paravalvular leak at 30 days. <strong>Conclusions: </strong>Portico valve implantation with the FlexNav DS was associated with an excellent safety profile at 30 days.
DOI: 10.5281/zenodo.5141785
title: Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System

description: Dataset from Fontana GP, Bedogni F, Groh M, Smith D, Chehab BM, Garrett HE Jr, Yong G, Worthley S, Manoharan G, Walton A, Hermiller J, Dhar G, Waksman R, Ramana RK, Mahoney P, Asch FM, Chakravarty T, Jilaihawi H, Makkar RR. Safety Profile of an Intra-Annular Self-Expanding Transcatheter Aortic Valve and Next-Generation Low-Profile Delivery System. JACC Cardiovasc Interv. 2020 Nov 9;13(21):2467-2478. doi: 10.1016/j.jcin.2020.06.041. Epub 2020 Jul 20. PMID: 33153563. <strong>Abstract</strong> <strong>Objectives: </strong>The aim of this study was to characterize the safety profile of an intra-annular self-expanding valve with a next-generation low-profile delivery system (DS). <strong>Background: </strong>Key design modifications to the FlexNav DS include the addition of a hydrophilic-coated, integrated sheath and stability layer to facilitate gradual, controlled deployment in vessels with diameter ≥5 mm. <strong>Methods: </strong>Patients were pooled from 2 concurrent prospective, multicenter, single-arm studies (FlexNav DS arm of PORTICO IDE [Portico Re-Sheathable Transcatheter Aortic Valve System U.S. IDE Trial] [n = 134] and the FlexNav EU CE Mark Study [n = 46]) for the analysis. The primary endpoint was Valve Academic Research Consortium-2-defined major vascular complications at 30 days. Clinical outcomes and valve performance were assessed through 30 days by an independent clinical events committee and an echocardiography core laboratory, respectively. <strong>Results: </strong>One hundred forty high-risk and 40 extreme-risk subjects enrolled between October 15, 2018, and December 10, 2019, from 28 sites in the United States, Australia, and Europe who underwent attempted transfemoral Portico valve implantation were included. The mean age was 85.1 ± 5.6 years, 60% were women, the mean Society of Thoracic Surgeons score was 5.3%, and 96.1% presented with ≥1 frailty factor. Technical device success was 96.7%. At 30 days, the rate of major vascular complications was 5.0%, with 4.4% of complications adjudicated as access site-related (3.3% transcatheter aortic valve replacement DS access site-related). Death (0.6%) and disabling stroke (1.1%) were rare. The rate of new permanent pacemaker implantation was 15.4%. Echocardiography revealed a mean gradient of 7.1 ± 3.2 mm Hg, mean valve area of 1.77 ± 0.41 cm<sup>2</sup>, and a 4.1% rate of moderate paravalvular leak at 30 days. <strong>Conclusions: </strong>Portico valve implantation with the FlexNav DS was associated with an excellent safety profile at 30 days.